| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events (NCT07729475) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2026-07-27 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants (NCT07722299) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2026-07-21 |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease (NCT07647133) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2026-06-15 |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism (NCT07646535) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2026-06-12 |
| A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens (NCT07579936) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2026-04-30 |
| Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (NCT07486453) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2026-03-09 |
| SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a) (NCT07745114) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2026-01-04 |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension (NCT07654140) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-12-09 |
| Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects (NCT07384104) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-10-19 |
| Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants (NCT07174830) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-09-06 |
| Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients (NCT07079579) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-08-01 |
| SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population (NCT07051603) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-06-09 |
| Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants (NCT06830954) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-02-01 |
| A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD) (NCT07716618) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2025-01-17 |
| Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan (NCT07704697) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2024-11-23 |
| SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies (NCT06737081) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2024-09-14 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia (NCT07253584) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2023-12-19 |
| A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia (NCT07295418) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2023-10-23 |
| Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis (NCT06720025) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2023-09-19 |
| A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia (NCT07278830) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2023-06-02 |
| To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects (NCT07030504) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2023-01-10 |
| Evaluating the Safety and Efficacy of the G-stream® Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery (NCT05780359) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2022-05-27 |
| The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency (NCT06883656) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2022-03-15 |
| To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk (NCT07028320) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2021-12-03 |
| To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil (NCT06465264) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2021-04-29 |
| Sirolimus DEB in Coronary Bifurcation Lesions (NCT04896177) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2021-03-18 |
| SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease (NCT06016036) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2020-12-08 |
| Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults (NCT04747392) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2020-08-19 |
| SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin (NCT05801627) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2020-05-06 |
| SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (NCT05782192) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2019-06-13 |
| G56W1 in Women With Postmenopausal Osteoporosis (NCT03720886) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2018-10-01 |
| Recombinant SeV-hFGF2/dF Injection for PAOD (NCT03668353) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2018-09-05 |